A new study in Cell Death Discovery identified PRMT6 as a driver of blood vessel growth in colorectal cancer, linking the protein-arginine methyltransferase to angiogenesis mechanisms that can support tumor expansion and metastasis. Researchers described how PRMT6 promotes vascularization pathways within the tumor context, expanding the molecular map of how colorectal tumors build their microenvironment. The work frames PRMT6 as a potential therapeutic entry point because angiogenesis is tightly tied to nutrient delivery and growth capacity. If validated in broader preclinical models, the biology could inform target selection or combination strategies aimed at limiting tumor vascular support. The findings arrive as cancer drug discovery teams continue to prioritize mechanisms that affect tumor microenvironment formation, not just tumor-intrinsic signaling. For translational teams, the next steps implied by the study are target engagement and therapeutic tractability: confirming PRMT6 dependency across tumor subtypes and evaluating whether inhibiting PRMT6 alters angiogenic output in vivo.